Sequoia Vaccines

Sequoia Vaccines is a private, clinical-stage biotech tackling antimicrobial resistance and oncology with a diversified pipeline. Its lead asset, SEQ-400, is a FimH vaccine for recurrent UTIs, supported by small-molecule programs for ovarian/uterine cancer and cystic fibrosis-related infections. Founded in 2012 (with roots dating to 1999), the company is led by an experienced team, holds a robust patent portfolio, and operates in large, underserved markets with significant unmet medical need. Its strategy aligns with global public health initiatives to reduce antibiotic dependence.

Proprietary plant-based purification and characterization technology used to discover novel chemical scaffolds from a global library of plants, enabling vaccine and small-molecule drug discovery.

In recurrent UTIs, competitors include other companies developing vaccines (e.g., FimH blockers, whole-cell vaccines) and non-antibiotic therapies. The ovarian cancer space is intensely competitive with numerous targeted therapies and immunotherapies in development. The CF infection market has existing antibiotics and novel anti-biofilm agents in development from both large pharma and biotech.